NASDAQ · Biotechnology

DFTX (DFTX) Stock

$42.36 +0.95% NASDAQ: DFTX Healthcare

Valuation

MetricValue
Price$42.36
Market Cap$4.62B
P/E Ratio-9.94
P/B Ratio6.73
P/S Ratio0.00
EPS (TTM)$-2.06
52-Week High$48.98
52-Week Low$12.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.42%
ROA-41.82%
ROCE-50.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio6.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-94.0M$-66.0M$-94.0M$-104.0M$-166.0M
Net Profit$-93.0M$-57.0M$-96.0M$-109.0M$-184.0M
EPS$-3.40$-1.53$-2.44$-0.15$-2.06
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$164.0M$170.0M$125.0M$302.0M$440.0M
Total Liabilities$12.0M$19.0M$46.0M$61.0M$108.0M
Cash$134.0M$142.0M$100.0M$274.0M$258.0M
Borrowings$0$0$14.0M$22.0M$0

Latest News

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva IPO-Edge.com · Jul 22, 2026 Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued? Simply Wall St. · Jul 22, 2026 How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story Simply Wall St. · Jul 22, 2026 Psychedelic drugs are going mainstream Financial Times · Jul 21, 2026 Definium Therapeutics Announces New Employee Inducement Grants Business Wire · Jul 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-46.0M$-50.0M$-64.0M$-79.0M$-132.0M
Investing Cash Flow$0$0$0$0$-152.0M
Financing Cash Flow$17.0M$17.0M$0$-8.0M$0
Net Cash Flow$53.0M$9.0M$-42.0M$174.0M$-16.0M
Free Cash Flow$-46.0M$-50.0M$-64.0M$-79.0M$-132.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-6.61%
Quick Ratio4.69
Interest Coverage-33.20
Return 1Y353.07%
Return 3Y869.46%
Return 5Y-4.29%

Ownership

Insiders Held1.33%
Institutions Held73.86%
Institutions Float Held74.86%
Institutional HolderSharesReport Date
Blackrock Inc.8,480,2302026-03-31
Driehaus Capital Management, LLC5,911,8892026-03-31
Avoro Capital Advisors LLC5,000,0002026-03-31
Janus Henderson Group PLC3,556,0412026-03-31
Deep Track Capital, Lp3,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
FTRE $18.43 +4.18% -1.26 $1.75B 0.00%
KOD $41.58 -2.16% -8.11 $2.60B 0.00%
NRIX $24.11 -0.17% -6.41 $2.50B 0.00%

About DFTX

DFTX stock trades at $42.36 with a market capitalization of $4.62B. The stock is valued at a price-to-earnings (P/E) ratio of -9.94, price-to-book of 6.73, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.88 and $48.98, and currently trades 13.5% below its 52-week high.

On profitability, DFTX generates a return on equity (ROE) of -55.42%, return on capital employed of -50.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides